- Home
- DCI vs PCVX Comparison
DCI vs PCVX Comparison
Compare DCI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCI
- PCVX
- Stock Information
- Founded
- DCI 1915
- PCVX 2013
- Country
- DCI United States
- PCVX United States
- Employees
- DCI N/A
- PCVX N/A
- Industry
- DCI Pollution Control Equipment
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- DCI Industrials
- PCVX Health Care
- Exchange
- DCI Nasdaq
- PCVX Nasdaq
- Market Cap
- DCI 8.7B
- PCVX 13.2B
- IPO Year
- DCI 1987
- PCVX 2020
- Fundamental
- Price
- DCI $68.28
- PCVX $78.14
- Analyst Decision
- DCI Hold
- PCVX Strong Buy
- Analyst Count
- DCI 4
- PCVX 9
- Target Price
- DCI $74.00
- PCVX $149.38
- AVG Volume (30 Days)
- DCI 582.4K
- PCVX 1.1M
- Earning Date
- DCI 02-26-2025
- PCVX 02-25-2025
- Dividend Yield
- DCI 1.59%
- PCVX N/A
- EPS Growth
- DCI 16.62
- PCVX N/A
- EPS
- DCI 3.44
- PCVX N/A
- Revenue
- DCI $3,640,100,000.00
- PCVX N/A
- Revenue This Year
- DCI $5.29
- PCVX N/A
- Revenue Next Year
- DCI $5.19
- PCVX N/A
- P/E Ratio
- DCI $19.85
- PCVX N/A
- Revenue Growth
- DCI 6.13
- PCVX N/A
- 52 Week Low
- DCI $62.77
- PCVX $58.10
- 52 Week High
- DCI $78.95
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- DCI 42.87
- PCVX 32.14
- Support Level
- DCI $66.01
- PCVX $80.10
- Resistance Level
- DCI $69.09
- PCVX $81.70
- Average True Range (ATR)
- DCI 1.11
- PCVX 3.12
- MACD
- DCI 0.20
- PCVX -0.13
- Stochastic Oscillator
- DCI 73.70
- PCVX 5.68
About DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.6 billion in revenue and $544 million in operating income in its fiscal 2024.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.